The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Open accessAbstract
Paclitaxel is a broad‐spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent‐induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half‐life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Lei, M., Sha, S., Wang, X., Wang, J., Du, X., Miao, H., Zhou, H., Bai, E., Shi, J., & Zhu, Y. (2019) · RSC Advances · doi:10.1039/c9ra00276f · Cited by 34
Effects of Yellow, Green, and Different Blue Spectra on Growth of Potato Plantlets In Vitro
Li, R., Huang, W., Wang, X., Liu, X., & Xu, Z. (2018) · HortScience · doi:10.21273/hortsci12848-18 · Cited by 33
Enhancement of paclitaxel production by abscisic acid in cell suspension cultures of Taxus chinensis
Luo, J., Liu, L., & Wu, C.-T. (2001) · Biotechnology Letters · doi:10.1023/a:1010597802741 · Cited by 32
Pereira‐Silva, M., Alvarez‐Lorenzo, C., Concheiro, Á., Paiva‐Santos, A. C., Veiga, F., & Figueiras, A. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.10.013 · Cited by 32
Paclitaxel sensitivity correlates with P53 status and DNA fragmentation, but not G2/M accumulation
Rakovitch, E., Mellado, W., Hall, E. J., Pandita, T. K., Sawant, S. G., & Geard, C. R. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00109-1 · Cited by 31
Chen, H., Zhao, Z., Dong, Zhang, Huang, Zhu, & Zhang (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44220 · Cited by 29
Lu, H., Zha, S., Zhang, W., Wang, Q., Jiang, D., Xu, X., Zheng, X., Qiu, M., & Shan, C. (2021) · BMC Cancer · doi:10.1186/s12885-021-08441-z · Cited by 28
Praziquantel Synergistically Enhances Paclitaxel Efficacy to Inhibit Cancer Cell Growth
Wu, Z. H., Lu, M., Hu, L. Y., & Li, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051721 · Cited by 26
Effendi, W. I., Nagano, T., TACHIHARA, M. Y., Umezawa, K., Kiriu, T., Dokuni, R., Katsurada, M., Yamamoto, M., Kobayashi, K., & Nishimura, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s193789 · Cited by 22
Chen, Z., Wang, C., Li, T., Li, K., Yue, Y., Liu, X., Xu, H., Wen, Y., Zhang, Q., Han, M. H., et al. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0330 · Cited by 21
Greish, K. F., Parayath, N. N., Nehoff, H. L., Norton, S. E., Highton, A. J., Taurin, S., & Kemp, R. A. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s110251 · Cited by 20
Nanoformulated Paclitaxel and AZD9291 Synergistically Eradicate non-small-cell Lung Cancers In Vivo
Wang, X.-S., Zhang, L., Li, X., Kong, D.-J., Hu, X.-C., Ding, X.-Z., Yang, J.-Q., Zhao, M.-Q., He, Y., Lam, K. S., et al. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0355 · Cited by 17
pH‐sensitive Podophyllotoxin carrier for cancer cells specific delivery
Fan, L., Wu, H., Zhang, H., Li, F., & Yang, T. (2009) · Polymer Composites · doi:10.1002/pc.20765 · Cited by 14
Polymeric Nanoparticles: In Vivo Toxicological Evaluation, Cardiotoxicity, and Hepatotoxicity
García, S. C., Guterres, S. S., Bubols, G., Bulcão, R., Charão, M. F., & Pohlmann, A. R. (2013) · Nanomedicine and nanotoxicology · doi:10.1007/978-1-4614-8993-1_14 · Cited by 13
Nakao, Y., & Fusetani, N. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00043-5 · Cited by 13
Takashima, T., Kawajiri, H., Nishimori, T., Tei, S., Nishimura, S., Yamagata, S., Tokunaga, S., Mizuyama, Y., Sunami, T., Tezuka, K., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12233 · Cited by 13
Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model
Kitayama, J., Ishigami, H., Yamaguchi, H., Yamada, J., Soma, D., Miyato, H., Kamei, T., Lefor, A. K., & Sata, N. (2017) · Pleura and Peritoneum · doi:10.1515/pp-2017-0002 · Cited by 12
Cited by
Natural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 607
Dhyani, P., Quispe, C., Sharma, E., Bahukhandi, A., Sati, P., Attri, D. C., Szopa, A., Sharifi-Rad, J., Docea, A. O., Mardare, I., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02624-9 · Cited by 483
Self-citationDiosgenin: An Updated Pharmacological Review and Therapeutic Perspectives
Semwal, P., Painuli, S., Abu-Izneid, T., Rauf, A., Sharma, A., Daştan, S. D., Kumar, M., Alshehri, M. M., Taheri, Y., Das, R., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1035441 · Cited by 195
Self-citationKitic, D., Miladinovic, B., Randjelovic, M., Szopa, A., Sharifi-Rad, J., Calina, D., & Seidel, V. (2022) · Plants · doi:10.3390/plants11141885 · Cited by 96
Self-citationMyricetin: Targeting signaling networks in cancer and its implication in chemotherapy
Javed, Z., Khan, K., Herrera-Bravo, J., Naeem, S., Iqbal, M. J., Raza, Q., Sadia, H., Raza, S., Bhinder, M., Calina, D., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02663-2 · Cited by 93
Self-citation
Metadata
- Authors
- Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., Živković, J., Cruz-Martins, N., Klimek-Szczykutowicz, M., Ekiert, H., Choudhary, M. I., Ayatollahi, S. A., Tynybekov, B., Kobarfard, F., Muntean, A. C., Grozea, I., Daştan, S. D., Butnariu, M., Szopa, A., & Calina, D.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 2021
- Issue
- 1
- Pages
- 3687700-3687700
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W3205724362
- Cited by
- 298
- References
- 217
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
